In this episode of Meeting Mic, we bring you pearls and perspectives in metastatic breast cancer from the American Society of Clinical Oncology 2026.

In an interview, Shimoli Barot, MD, discusses a genomic test which could be used to identify patients with ER-positive, HER2-negative breast cancer who may be able to avoid chemotherapy.

Next, Erika P. Hamilton, MD, discusses the HER2-CLIMB05 trial for patients with HER2-positive metastatic breast cancer.

And, Sherry Shen, MD, discusses lifestyle and survivorship for patients with breast cancer, specifically with GLP-1 use.

Read the full coverage here:

VIDEO: Genetic test helps identify patients with breast cancer who may avoid chemotherapy

Source: Healio Interviews

VIDEO: Tucatinib plus trastuzumab, pertuzumab safe for HER2-positive breast cancer

Source: Hamilton EP. Abstract 1005. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago.

VIDEO: Less weight loss, improved survival for GLP-1 use in women with breast cancer

Source: Shen S. Optimizing breast cancer survivorship: Addressing lifestyle, weight management, and psychological health. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago.

'Critically important': Upfront sacituzumab govitecan combo benefits breast cancer subset

Source: Kalinsky K, et al. Abstract LBA1000. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago.

'Real value': Remote program significantly improves physical function in breast cancer

Source: Ligibel JA, et al. Abstract 12010. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago.

Barot and Shen report no relevant financial disclosures. Hamilton reports receiving research funding from Abbvie, Accutar Biotechnology, Artios, Arvinas, AstraZeneca, AtlasMedx, BeiGene, BeOne Medicines, Bicycle Therapeutics, Biohaven Pharmaceuticals, BioNTech, Compugen, Cullinan, Daiichi Sankyo, Dantari, Day One Biopharmaceuticals, Duality Biologics, Ellipses Pharma, Elucida Oncology, Exelixis, FujiFilm, Genmab, Gilead Sciences, H3 Biomedicine, Iambic Therapeutics, Immunogen, Inspirna, InventisBio, Jacobio, Jazz Pharmaceuticals, K-Group Beta, Kind Pharmaceuticals, Lilly, Loxo Oncology, Mabspace Biosciences, Mabwell Bioscience, Marengo Therapeutics, MediLink Therapeutics, Merck, Mersana, Novartis, Olema, Orinove, Orum Therapeutics, Pfizer, Pionyr Immunotherapeutics, Prelude Therapeutics, Profound Bio, Regeneron, Relay Therapeutics, Rgenix, Roche/Genentech, SeaGen, Shattuck Labs, Simcha Therapeutics, Stemline Therapeutics, Sutro, Systimmune, Taiho, Tesaro, TheRas, Treadwell Therapeutics, Verastem, Xadcera Biopharmaceutical and Zymeworks; and consulted or advised for ADC Therapeutics, Arvinas, AstraZeneca, BeOne Medicines, BicycleTx, BioNTech, Boehringer Ingelheim, Boundless Bio, Bristol-Myers Squibb, Daiichi Sankyo, Gilead Sciences, Halda Therapeutics, Hexagon Bio, Immunome, Incyclix Bio, Janssen, Jazz Pharmaceuticals, Lilly, Merck, Mersana Therapeutics, Novartis, Pfizer, Precede Biosciences, Pyxis Oncology, Rigel Pharmaceuticals, Roche/Genentech, Samsung Bioepis, Shorla Pharma and Stemline Therapeutics.

In this episode of Meeting Mic, Mark Leiser, Healio's Oncology Insider, joins Shikha Jain, MD, to discuss top presentations, as well as pearls and perspectives from ASCO Annual Meeting.

· Daraxonrasib offers 'transformational' benefit in metastatic pancreatic cancer

· GLP-1s demonstrate 'large' & 'consistent' protective effects against cancer metastases

· Trial of early cancer detection test misses primary endpoint; secondary data 'promising'

· 'This matters': Hem/onc fellows embrace AI but lack formal training to guide its use

· Hem/onc 'bootcamp' significantly improves fellows' knowledge, clinical confidence

· Immunotherapy combination may improve outcomes in unresectable liver cancer

· Abemaciclib may be new standard for 'challenging' sarcoma subtype

For more of the latest breaking news in oncology, be sure to visit Oncology Insider.

We'd love to hear from you! For more from Dr. Jain, follow her on X: @ShikhaJainMD and on Instagram: @shikhajainmd. For more from Leiser, follow him on X: @_MarkLeiser or on LinkedIn.

Jain and Leiser report no relevant financial disclosures.

In this episode of Meeting Mic, we bring you pearls and perspectives from the Association of Vision and Research in Ophthalmology 2026.

Jason Greenfield, MD, MBA, Alon Harris, MS, PhD, FARVO, and Yash Lahoti spoke with Healio about their study, which was designed to look at some of the unknown risk factors for glaucoma. 00:37

Next, Michael Zhu, a medical student at Duke University School of Medicine, told Healio about his presentation about retina imaging and how it may reveal links to Parkinson's disease. 06:12

And, Iris Fang-Yu Hu, MD, discusses her presentation on how using visual prompts helped improve glaucoma detection by a large language model. 08:35

Top headlines from the meetings. 09:31

Read the full coverage here:

Glaucoma, hypertension may be linked to dementia risk

Source: Greenfield J, et al. Artificial intelligence ready and exploratory atlas for diabetes insights: The association between glaucoma, hypertension, and cognitive performance. Presented at: Association for Research in Vision and Ophthalmology meeting; May 3-7, 2026; Denver.

Imaging reveals link between inner nuclear layer thickness, Parkinson's disease

Source: Zhu M, et al. Macular retinal layer thickness in early Parkinson's disease. Presented at: Association for Research in Vision and Ophthalmology meeting; May 3-7, 2026; Denver.

Reference images help AI model detect glaucoma

Source: Hu I, et al. Providing reference images to LLMs improves glaucoma detection from fundus photos. Presented at: Association for Research in Vision and Ophthalmology meeting; May 3-7, 2026; Denver.

Smoking may be modifiable risk factor for myopia-related vision loss

Source: Flitcroft I, et al. Smoke gets in your eyes: Evidence that smoking is the first modifiable risk factor for myopia-related vision impairment. Presented at: Association for Research in Vision and Ophthalmology meeting; May 3-7, 2026; Denver.

Thyroid eye disease shows long-term progression in real-world dataset

Source: Ramesh S, et al. Disease progression in thyroid eye disease: Findings from a large real-world study in the United States. Presented at: Association for Research in Vision and Ophthalmology meeting; May 3-7, 2026; Denver.